Canaccord raised the firm’s price target on Guardant Health (GH) to $65 from $60 and keeps a Buy rating on the shares. The firm said they remain bullish following strong execution to start 2025 and raised their price target given increased estimates. They believe the shares remain undervalued due to Guardant’s established therapy selection business and progress in minimal residual disease and screening.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating
- Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Guardant Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Guardant Health price target raised to $60 from $55 at Barclays
- Guardant Health Reports Strong Q1 2025 Growth